# Autologous Transplant To End NMO Spectrum Disorder

> **NCT03829566** · PHASE2,PHASE3 · WITHDRAWN · sponsor: **Northwestern University**

## Conditions studied

- Neuromyelitis Optica
- Devic's Disease
- NMO Spectrum Disorder

## Interventions

- **DRUG:** Rituximab
- **DRUG:** Cyclophosphamide
- **DRUG:** Mesna
- **DRUG:** rATG
- **DRUG:** Methylprednisolone
- **DRUG:** G-CSF
- **BIOLOGICAL:** IVIg
- **BIOLOGICAL:** Autologous Stem Cells

## Key facts

- **NCT ID:** NCT03829566
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-11
- **Primary completion:** 2025-01
- **Final completion:** 2025-11-28
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Discontinued by Investigator
- **Last updated:** 2019-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03829566

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03829566, "Autologous Transplant To End NMO Spectrum Disorder". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03829566. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*